1. Home
  2. CINGW vs ESNT Comparison

CINGW vs ESNT Comparison

Compare CINGW & ESNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • ESNT
  • Stock Information
  • Founded
  • CINGW N/A
  • ESNT 2008
  • Country
  • CINGW United States
  • ESNT Bermuda
  • Employees
  • CINGW 13
  • ESNT N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • ESNT Property-Casualty Insurers
  • Sector
  • CINGW Health Care
  • ESNT Finance
  • Exchange
  • CINGW Nasdaq
  • ESNT Nasdaq
  • Market Cap
  • CINGW N/A
  • ESNT N/A
  • IPO Year
  • CINGW 2021
  • ESNT 2013
  • Fundamental
  • Price
  • CINGW $0.04
  • ESNT $55.08
  • Analyst Decision
  • CINGW
  • ESNT Buy
  • Analyst Count
  • CINGW 0
  • ESNT 7
  • Target Price
  • CINGW N/A
  • ESNT $61.71
  • AVG Volume (30 Days)
  • CINGW N/A
  • ESNT 888.8K
  • Earning Date
  • CINGW N/A
  • ESNT 05-02-2025
  • Dividend Yield
  • CINGW N/A
  • ESNT 2.25%
  • EPS Growth
  • CINGW N/A
  • ESNT 5.38
  • EPS
  • CINGW N/A
  • ESNT 6.85
  • Revenue
  • CINGW N/A
  • ESNT $1,242,904,000.00
  • Revenue This Year
  • CINGW N/A
  • ESNT $4.19
  • Revenue Next Year
  • CINGW N/A
  • ESNT $4.79
  • P/E Ratio
  • CINGW N/A
  • ESNT $8.04
  • Revenue Growth
  • CINGW N/A
  • ESNT 12.00
  • 52 Week Low
  • CINGW N/A
  • ESNT $51.61
  • 52 Week High
  • CINGW N/A
  • ESNT $65.33
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • ESNT 47.14
  • Support Level
  • CINGW N/A
  • ESNT $54.36
  • Resistance Level
  • CINGW N/A
  • ESNT $56.58
  • Average True Range (ATR)
  • CINGW 0.00
  • ESNT 1.88
  • MACD
  • CINGW 0.00
  • ESNT -0.07
  • Stochastic Oscillator
  • CINGW 0.00
  • ESNT 48.40

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: